Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal CompositionMin Yu, Shyamala Maheswaran, Aditya Bardia et al.|Science|2013Cited by 2.5k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L. Telli, Andrea L. Richardson, Kirsten M. Timms et al.|Clinical Cancer Research|2016Cited by 1.2k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerAditya Bardia, Kevin Kalinsky, Ingrid A. Mayer et al.|New England Journal of Medicine|2019Cited by 846
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Linda T. Vahdat, Ingrid A. Mayer et al.|Journal of Clinical Oncology|2017Cited by 407
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokineticsAllyson J. Ocean, David M. Goldenberg, Linda T. Vahdat et al.|Cancer|2017Cited by 235